v3.25.3
Consolidated Statements of Operations - USD ($)
12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]    
Collaboration revenue $ 1,000,000 $ 18,626
Operating expenses:    
Research and development 8,355,304 5,737,252
General and administrative 8,488,811 6,130,845
Total operating expenses 16,844,115 11,868,097
Loss from operations (15,844,115) (11,849,471)
Foreign exchange (loss) gain (112,985) 84,293
Other income 720,102 4,327,946
Amortization of debt discount (556,089)
Loss before provision for income taxes (15,793,087) (7,437,232)
Provision for income taxes (218,400)
Net loss (16,011,487) (7,437,232)
Accrual of cumulative dividends on Series 5 convertible preferred stock (101,250)
Net loss attributable to common stockholders $ (16,112,737) $ (7,437,232)
Per share information:    
Net loss per share, basic $ (3.95) $ (11.35)
Net loss per share, diluted $ (3.95) $ (11.35)
Weighted average shares outstanding, basic 4,081,296 655,240
Weighted average shares outstanding, diluted 4,081,296 655,240

Source